Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

• Main Authors: Niurys de Castro-Suárez (Author), Mirjam N. Trame (Author), Mayra Ramos-Suzarte (Author), José M. Dávalos (Author), Raymed A. Bacallao-Mendez (Author), Anaelys R. Maceo-Sinabele (Author), Víctor Mangas-Sanjuán (Author), Gledys Reynaldo-Fernández (Author), Leyanis Rodríguez-Vera (Author)
• Format: Book
• Published: MDPI AG, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic mo...